Corrections and Retraction

CORRECTIONS

APPLIED MATHEMATICS, POPULATION BIOLOGY. For the article “Global asymptotic coherence in discrete dynamical systems,” by David J. D. Earn and Simon A. Levin, which appeared in issue 11, March 14, 2006, of Proc Natl Acad Sci USA (103:3968–3971; first published March 7, 2006; 10.1073/pnas.0511000103), the authors note that on page 3971, inequality 25 holds only for particular classes of matrices \( \mathbf{M} \), and strict inequality never holds (Theorem 5.6.9, page 297 of ref. 12). The authors are grateful to Jinhu Li for recognizing this error. The argument given in the paper proves the following revised version of Theorem 1 (page 3970).

Theorem 1. Let \( X \) be a convex subset of a Banach space \( \mathbb{B} \), and suppose the fundamental map \( F : X \to X \) is differentiable at each \( x \in X \). Suppose that \( [D_x F] \) is bounded in \( X \), and let \( r = \sup_{x \in X} \| [D_x F] \| \). Suppose \( \mathbf{M} \) is a stochastic \( n \times n \) matrix, and define \( \mathbf{M} \) as in Lemma 2. Let \( \| \cdot \| \) be any matrix norm for which there exists a compatible monotone vector norm, and let \( \mu = \| \mathbf{M} \| \). If \( r \mu < 1 \), then the full map \( F : X^n \to X^n \), defined by \( \bar{F}(\mathbf{x}) = \mathbf{M} \cdot \bar{F}(\mathbf{x}) \), is globally asymptotically coherent, i.e., every initial state \( \mathbf{x}_0 \in X^n \) asymptotically approaches a coherent trajectory. If \( r < 1 \), then \( \bar{F} \) has a globally asymptotically stable fixed point.

The authors note that all \( \ell_p \) norms are monotone, so the matrix norm \( \| \cdot \| \) in the theorem can, for example, be taken to be any matrix norm induced by an \( \ell_p \) vector norm. The simplest examples are the maximum column sum and maximum row sum matrix norms, which are induced by the \( \ell_1 \) and \( \ell_\infty \) vector norms, respectively. The original statement of Theorem 1 is valid for some classes of matrices (for example, if \( \mathbf{M} \) is normal or triangular) but may not be true in the generality stated. In applications, the matrix \( \mathbf{M} \) will almost always be primitive; if \( \mathbf{M} \) is not primitive, then \( \mu \geq 1 \), in which case the theorem has nontrivial content only in the situation where \( r < 1 \).

The authors also note the following typographical errors, which do not affect the conclusions of the article. On page 3968, Eq. 7 should read: “\( \mathbf{M} \cdot \mathbf{e} = \mathbf{e} \)” On page 3969, Eq. 14 should read:

\[
\mathbf{M} = \begin{pmatrix} m_1 & 1 - m_1 \\ 1 - m_2 & m_2 \end{pmatrix}
\]

and on page 3970, left column, first full paragraph, “unless \( m_1 = m_2 = 0 \) . . . or \( m_1 = m_2 = 1 \) ” should read: “unless \( m_1 = m_2 = 1 \) . . . or \( m_1 = m_2 = 0 \) .” On page 3971, in Eq. 24d, there should be no primes (e.g., “\( x_1' - x_n' \) ” should read: “\( x_1 - x_n \) ”).


www.pnas.org/cgi/doi/10.1073/pnas.0609567103

BIOCHEMISTRY. For the article “Enzyme–microbe synergy during cellulose hydrolysis by Clostridium thermocellum,” by Yanpin Lu, Yi-Heng Percival Zhang, and Lee R. Lynd, which appeared in issue 44, October 31, 2006, of Proc Natl Acad Sci USA (103:16165–16169; first published October 23, 2006; 10.1073/pnas.0605381103), the authors note that on page 16167, at the top of the right column, the references to steady states 1 and 2 are switched, as may be seen from inspection of Table 1. The corrected text should read: “In continuous culture, a \( D_{ET}^{FS} \) value of 2.72 is obtained based on microbial and SSF steady states 2, for which \( \approx 75\% \) of the feed cellulose was hydrolyzed. For microbial and SSF steady states 1, for which \( \approx 66\% \) hydrolysis was achieved, \( D_{ET}^{EM} = 4.70 \). Values for enzyme–microbe synergy on a pellet cellulase basis, \( D_{ET}^{EM} \) are quite similar to values observed in continuous culture: 3.05 for microbial and SSF steady states 2 and 4.61 for microbial and SSF steady states 1.” This error does not affect the conclusions of the article.

www.pnas.org/cgi/doi/10.1073/pnas.0609567103

MEDICAL SCIENCES. For the article “Human cancers express a mutator phenotype,” by Jason H. Bielas, Keith R. Loeb, Brian P. Rubin, Lawrence D. True, and Lawrence A. Loeb, which appeared in issue 48, November 28, 2006, of Proc Natl Acad Sci USA (103:18238–18242; first published November 15, 2006; 10.1073/pnas.0607603103), several references to nucleotide instability (NIN) should have appeared as point mutation instability (PIN). On page 18238, in the key terms, “nucleotide instability (NIN)” should be replaced with “point mutation instability (PIN).” On page 18239, in the last sentence of the first paragraph of the Discussion, “nucleotide instability or NIN” should read: “point mutation instability or PIN.” Last, on page 18239, in the last sentence of the second paragraph of the Discussion, “an increase in NIN” should read: “an increase in PIN.” The online version has been corrected. These errors do not affect the conclusions of the article.

www.pnas.org/cgi/doi/10.1073/pnas.0610370103
RETRACTION

For the article “A common mutational pattern in Cockayne syndrome patients from xeroderma pigmentosum group G: Implications for a second XPG function,” by Thierry Nouspikel, Philippe Lalle, Steven A. Leadon, Priscilla K. Cooper, and Stuart G. Clarkson, which appeared in issue 7, April 1, 1997, of Proc Natl Acad Sci USA (94:3116–3121), the editors wish to note that Steven Anthony Leadon has submitted a letter to PNAS that states, “I have recently had the opportunity to review some of the raw data used for Figure 6 in this paper in the above-referenced publication and it is clear that the data as reported in this figure cannot be relied upon. Therefore, I request that you retract Figure 6 of this paper.” Fig. 6 is hereby retracted.

Leadon’s request for retraction of Fig. 6 is part of a Voluntary Exclusion Agreement Leadon entered into with the U.S. Department of Health and Human Services (HHS) through the Public Health Service and the Office of Research Integrity in the case of Steven Anthony Leadon, University of North Carolina. The specific terms of the Agreement between Leadon and HHS are published in the Notice of Findings of Scientific Misconduct from HHS [71 Federal Register 110 (June 8, 2006/Notices), pp 33308–33309].

The editors also wish to note that the other authors of the PNAS article (Thierry Nouspikel, Philippe Lalle, Priscilla K. Cooper, and Stuart G. Clarkson) and the communicating member (Philip C. Hanawalt) have submitted the following statement to PNAS: “Figs. 1 through 5 in the PNAS paper document experiments performed by Thierry Nouspikel and Philippe Lalle in Stuart Clarkson’s laboratory in Geneva, in which it was established that XP-G patients with severe early onset Cockayne syndrome (CS) produce truncated and unstable XPG proteins but that a pair of mildly affected XP-G siblings without symptoms of CS are able to synthesize a full-length product from one allele with a missense mutation. The conclusion was that XPG must have a second function in addition to its role as a structure-specific nuclease in nucleotide excision repair. The validity of that conclusion is not challenged by the retraction of Fig. 6, and the abstract stands correct. The conclusions of the paper have been confirmed independently by a number of laboratories [e.g., Shiomi et al. (2004) Mol Cell Biol 24:3712–3719; Tian et al. (2004) Mol Cell Biol 24:2237–2242; Zafeiriou et al. (2001) Pediatr Res 49:407–412; Emmert et al. (2002) J Invest Dermatol 118:972–982].”

Solomon H. Snyder, Senior Editor, PNAS

www.pnas.org/cgi/doi/10.1073/pnas.0609759103
Human cancers express a mutator phenotype

Jason H. Bielas, Keith R. Loeb*, Brian P. Rubin, Lawrence D. True, and Lawrence A. Loeb†

Department of Pathology, University of Washington, Seattle, WA 98195

Cancer cells contain numerous clonal mutations, i.e., mutations that are present in most or all malignant cells of a tumor and have presumably been selected because they confer a proliferative advantage. An important question is whether cancer cells also contain a large number of random mutations, i.e., randomly distributed unselected mutations that occur in only one or a few cells of a tumor. Such random mutations could contribute to the morphologic and functional heterogeneity of cancers and include mutations that confer resistance to therapy. We have postulated that malignant cells exhibit a mutator phenotype resulting in the generation of random mutations throughout the genome. We have recently developed an assay to quantify random mutations in human tissue with unprecedented sensitivity. Here, we report measurements of random single-nucleotide substitutions in normal and neoplastic human tissues. We report that, in addition to tumors, see below) were then coded so that their identity was unknown to all investigators conducting the mutation assays. The mutation frequency we observed in the normal samples (squamous epithelium, renal cortex, colon epithelium, skeletal muscle) is less than 1 in 10^6 (Table 1), consistent with the frequency we measured (1.6 × 10^-8) in cultured human diploid fibroblasts (9). In total, we assayed >500 megabases of DNA from normal tissues and detected mutations in only one sample. This exceptional sample (the inflamed renal cortex in Fig. 2) was distinguished by lymphocytic infiltration, consistent with the concept that inflammation may be a key factor in the neoplastic process (17, 18). The low frequency of random mutations we measured at intron VI of p53 is consistent with the frequencies observed in circulating human lymphocytes at the HPRT locus by selection for 6-thioguanine resistance (19).

Results

The RMC Assay Quantifies Random Point Mutations in Single DNA Molecules from Human Tissue. We have adapted the RMC assay for application to human tissue, as illustrated in Fig. 1. The assay involves initial enrichment of the mutational target sequence, a TaqI restriction site (TCGA) in intron VI of p53, by repeated hybridization to a biotin-labeled probe and magnetic bead separation. Nucleotide substitutions in the enriched target sequence that render it resistant to TaqI cleavage are then quantified by dilution to single molecules followed by real-time quantitative PCR (QPCR) amplification. By avoiding the limitations associated with sequencing of large populations of DNA molecules and misincorporation during PCR amplification, the RMC assay provides greater sensitivity than previous methods. We have shown that mutations in the target sequence are genetically neutral, i.e., that they impart neither positive nor negative selection to cells in culture (9).

Random Mutation Frequency in Normal Human Tissue. We analyzed a set of tissue pairs, each pair consisting of matching normal and tumor tissue from different patients. All samples (including the concurrently processed paired tumors, see below) were then coded so that their identity was unknown to all investigators conducting the mutation assays. The mutation frequency we observed in the normal samples (squamous epithelium, renal cortex, colon epithelium, skeletal muscle) is less than 1 in 10^6 (Table 1), consistent with the frequency we measured (1.6 × 10^-8) in cultured human diploid fibroblasts (9). In total, we assayed >500 megabases of DNA from normal tissues and detected mutations in only one sample. This exceptional sample (the inflamed renal cortex in Fig. 2) was distinguished by lymphocytic infiltration, consistent with the concept that inflammation may be a key factor in the neoplastic process (17, 18). The low frequency of random mutations we measured at intron VI of p53 is consistent with the frequencies observed in circulating human lymphocytes at the HPRT locus by selection for 6-thioguanine resistance (19).


The authors declare no conflict of interest.

This article is a PNAS direct submission.

FREely available online through the PNAS open access option.

Abbreviations: QPCR, quantitative PCR; RMC, random mutation capture.

See Commentary on page 18033.

*Present address: Department of Laboratory Medicine, Box 357110, University of Washington, Seattle, WA 98115-7110.

†To whom correspondence should be addressed: Department of Pathology, Box 357705, University of Washington, Seattle, WA 98115-7705. E-mail: larloeb@u.washington.edu.

© 2006 by The National Academy of Sciences of the USA.
Elevated Random Mutation Frequency in Cancers. To assess the prevalence of random mutations in human cancers, we initially examined a lymph node involved by non-Hodgkin’s lymphoma. The mutation frequency was $300 \times 10^{-8}$, 190-fold greater than that observed in cultured human fibroblasts ($1.6 \times 10^{-10}$) (Table 1). For comparison, Table 1 records the mutation frequency of $175 \times 10^{-8}$ that we found for normal human diploid fibroblasts treated with an extremely high dose (1 mg/ml) of the potent mutagen N-ethyl-N-nitrosourea (9).

The well demarcated, sporadic tumors belonging to the matched tissue pairs were examined histologically to confirm the diagnosis (Fig. 2). All tumors were highly anaplastic, containing cells that displayed differences in morphology, size, and nuclear staining (Fig. 2). In total we screened >100 megabases of target sequence in tumor DNA (Table 1). In contrast to the paucity of mutations in normal tissues, all tumors exhibited high levels of sequence in tumor DNA (Table 1). In contrast to the paucity of staining (Fig. 2). In total we screened cells that displayed differences in morphology, size, and nuclear diagnosis (Fig. 2). All tumors were highly anaplastic, containing matched tissue pairs were examined histologically to confirm the observation that clonal single-nucleotide substitutions in human cancer cells also display greatly elevated frequencies of random nucleotide point mutations (point mutation instability (16)). The mutator phenotype hypothesis states that normal cancer cells express a mutator phenotype at the single-nucleotide level (16). The mutator phenotype hypothesis states that normal cancer cells express a mutator phenotype at the single-nucleotide level (16). The mutator phenotype hypothesis states that normal cancer cells express a mutator phenotype at the single-nucleotide level (16).

The Spectrum of Random Mutations in Human Cancers. Every mutation that rendered DNA resistant to TaqI cleavage was verified by sequencing. Sequence analysis of all tumor mutations indicates that the majority were not extensively expanded and suggests that they arose from distinct mutational events that occurred after the last clonal expansion (Fig. 3). In every case, multiple occurrences of the same mutation were scored as one single mutational event, as in Fig. 3. All mutations were single-base substitutions, the most frequent being C-G to T-A transitions and T-A to G-C transversions. The transitions in particular are consistent with, but not necessarily diagnostic of or limited to, misincorporation by replicative DNA polymerases in the absence of DNA damage (20). In contrast to these results, T-A to A-T transversions were the most frequent substitutions detected in N-ethyl-N-nitrosourea-treated human fibroblasts by using the same procedure (9).

Discussion
Our understanding of human cancer, and our ability to treat and prevent it, depends critically on knowledge of the mechanisms and pathways of tumor evolution. It has become apparent that both genetic and epigenetic changes underlie tumorigenesis (21). Genetic instability in cancer cells is evidenced by chromosome aberrations (chromosomal instability or CIN); extensive chromosomal microheterogeneity has been observed among single metastatic cells that arose from the same tumor (22). Genetic instability is further manifested by changes in the length of microsatellite sequences (microsatellite instability or MIN), as well as by clonal mutations, including mutations in oncogenes and tumor suppressor genes. We report here that the genomes of human cancer cells also display greatly elevated frequencies of random nucleotide point mutations (point mutation instability or PIN, in parallel with the above designations).

Our results provide strong support for the hypothesis that cancer cells express a mutator phenotype at the single-nucleotide level (16). The mutator phenotype hypothesis states that normal mutation rates are insufficient to account for the multiple mutations observed in human tumors, and that cancer cells must therefore incur increased rates of mutagenesis. The increased mutation would occur genome-wide, and would affect genes that are required for genomic stability. In principle then, an increase in PIN could contribute to both CIN and MIN, in accord with the observations that clonal single-nucleotide substitutions in many genes have been associated with both phenotypes (23–25).
Estimates of the frequency of nucleotide substitutions in human cancers have been largely restricted to documentation of clonally expanded mutations in tumor cell populations (26, 27). These studies used sequencing reactions containing populations of DNA molecules, and they did not score mutations present in only one or a few cells, because conventional sequencing technology does not permit detection of mutations present in <10% of cells. Thus, the reported consensus sequence is not informative of mutations that were not subject to extensive clonal expansion. Accordingly, conventional DNA sequencing vastly underestimates the number of mutations present in a tumor. To unmask the full extent of heterogeneity, it is necessary to measure random mutations, and to do this, it is necessary to analyze single DNA molecules.

We present here an analysis of mutation frequency in single DNA molecules from human tissues. Our estimate of the frequency of random mutation in normal tissues, <1 × 10⁻⁸ mutations per base pair (Table 1), represents an upper limit based on screening of 500 megabases of DNA. The mean mutation frequency we observed in tumors (210 × 10⁻⁸ mutations per base pair) is elevated at least 200-fold relative to matching normal tissue (Table 1).

Sequence analysis of all mutations detected in tumors indicates that most of the mutants are either not expanded or are not extensively expanded, but rather are present in only one or a few cells that constitute an individual tumor (Fig. 3). We note that, in determining mutation frequency, we scored multiple occurrences of the same mutation (expanded mutations) as a single mutational event, equivalent to a mutation we observed only once. Unexpanded mutations represent genetic changes that occurred after the last round of clonal expansion that included the mutated cells (28). The mutants that we detected multiple times (from 2 to 27 times) represent modest expansions affecting a small fraction of tumor cells. Because our mutational target is genetically neutral [i.e., confers neither a selective growth advantage nor a disadvantage (9)], expansion of cells harboring mutant sequences could reflect a proliferative advantage conferred by another mutation(s) elsewhere in the genome; in other words, expanded mutant sequences could be “passenger” or “piggy-back” mutations. Alternatively, they could occur simply by chance.

In the clinically manifest tumors we studied, unexpanded mutations are indicative of late occurrence in tumor evolution, the high random mutation frequency is indicative of ongoing expression of a mutator phenotype, and expanded mutations may be indicative of ongoing selection of advantageous mutations elsewhere in the genome. Importantly, the elevated frequency of mutations cannot be explained by increased rounds of proliferation alone, but must include an enhanced rate of mutation in tumors. This is so because (i) mutations at the target site are genetically neutral [there is no selection (9)] and (ii) expansion of distinct mutations by proliferation is scored as a single mutational event. In other words, because we report the same genetic change in multiple DNA molecules as one mutation, the calculated frequency of distinct unselected mutational events (Table 1) is unaffected by increased rounds of proliferation.

It is plausible that a mutator phenotype could be detrimental late in tumor evolution when the tumor is relatively well established and adapted, and that persistence of accelerated mutagenesis might therefore be selected against. However, mathematical models do not indicate that negative clonal selection would mitigate against a mutator phenotype (29, 30). Moreover, we find clear evidence for ongoing elevation of mutagenesis in at least some clinically detected tumors. Our evidence that enhanced mutagenesis is an ongoing process in at least some clinically manifest tumors carries the implication that intervention to inhibit this process may impede progression and metastasis after diagnosis.

Emerging data underscore the heterogeneity of mutations in tumors among different individuals and in cancer cells within each tumor. In colorectal cancer, for example, the progression from adenoma to carcinoma has been associated with sequential
Mutations in APC, K-ras, and p53 (31). Yet, only 7% of these tumors have mutations in all three genes, implying that multiple pathways are involved in colorectal tumorigenesis (32). Early DNA sequencing studies indicated that a limited number of cancer-related genes were mutated in individual tumors, and that these might provide targets for drug development (33). However, in breast and colon cancer, recent work (34) has revealed increasing complexity of clonally expanded mutations. Sequencing of 13,023 genes in 11 breast and 11 colorectal cancers yielded 89 and 126 different genes that were mutated, respectively (34). Moreover, only a small subset of these genes was found to be mutated at significant frequency in either cancer. The diversity of clonal mutations among tumors, theorized to be generated early in tumorigenesis by a mutator phenotype (35), together with the large number of late-arising random substitutions demonstrated here, emphasizes that the heterogeneity of mutations in tumors may be greater than has been appreciated.

The presence of large numbers of random mutations within tumors could limit the efficacy of targeted therapies. By the time a tumor is clinically detected it contains $10^{12}$ different single-nucleotide substitutions. Many of these mutations would alter the properties of the encoded proteins, including mutations that confer resistance to radio-, chemo-, and/or immunotherapy (36). Thus, increased genetic variability in newly diagnosed cancers could encompass a reservoir of mutations available for immediate clonal expansion upon initiation of treatment with any given agent, leading to rapid emergence of resistance. This concept provides a molecular basis for the observed clinical efficacy of combination therapy, because any single cell would be unlikely to contain mutations that confer resistance to agents with different mechanisms of cytotoxicity. It can be hypothesized that tumors with fewer random mutations should be treated more conservatively, whereas tumors with a higher frequency of random mutations should be treated more aggressively and with combination therapies. Thus, mutation frequency could provide a new index for stratification of tumors. One possibility is that mutation frequency will exhibit an overall positive association with tumor stage and grade, but that there will be significant variability within defined stages and grades. This variability, which may contribute to differences in within-group outcome, could help to guide therapy for individual patients.

### Materials and Methods

#### Tissues and DNA Isolation.
Tissues were obtained as anonymous samples from the Department of Pathology, University of Washington. The specimens were frozen in liquid nitrogen and stored at $-70^\circ$C. Hematoxylin/eosin-stained sections were reexamined by pathologists to confirm tissue identity and tumor diagnoses. Tissues were microdissected to obtain normal tissue samples that were free of detectable tumor cells and tumor samples that were composed of at least 90% tumor cells. Tissue samples (400 mg) were immersed in 20 ml of digestion buffer (800 mM guanidine-HCl/30 mM Tris-HCl, pH 8.0/30 mM EDTA/5% Tween-20/0.5% Triton X-100/2 mg/ml proteinase K/200 µg/ml RNase A) and thoroughly homogenized mechanically with an UltraTurrax T25 homogenizer (IKA Works, Wilmington, NC). The homogenate was incubated at 50°C for 2 h and applied to a prewashed 500/G genomic-tip column (Qiagen, Valencia, CA) for DNA recovery according to the manufacturer’s directions.

#### RMC Assay.
The procedure for quantification of random mutations (9) is outlined here with modifications for DNA from human tissues. Briefly, 400 µg of purified genomic DNA is incubated with the following restriction enzymes that do not cut the target sequence: 100 units each of PvuI and RsaI and 200 units each of EcoRI, EcoRV, and BamHI. The digested DNA is hybridized with a 100-fold excess of the complementary probe that contains dUMP in place of dTMP and a biotinylated nucleotide at the 5’ terminus. This complementary sequence was

### Table 1. Random mutation frequency in human tissues and cells

<table>
<thead>
<tr>
<th>Tissues</th>
<th>Nucleotides analyzed</th>
<th>Mutation frequency* $\times 10^6$</th>
<th>Neoplastic</th>
<th>Nucleotides analyzed</th>
<th>Mutation frequency* $\times 10^6$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Squamous epithelium</td>
<td>115</td>
<td>$&lt;1$</td>
<td>Ovarian carcinoma</td>
<td>18</td>
<td>75</td>
</tr>
<tr>
<td>Renal cortex</td>
<td>108</td>
<td>$&lt;1$</td>
<td>Perirenal liposarcoma</td>
<td>24</td>
<td>65</td>
</tr>
<tr>
<td>Colonic mucosa</td>
<td>115</td>
<td>$&lt;1$</td>
<td>Colonic adenocarcinoma</td>
<td>10</td>
<td>475</td>
</tr>
<tr>
<td>Inflamed renal cortex</td>
<td>55</td>
<td>4</td>
<td>Renal carcinoma</td>
<td>15</td>
<td>270</td>
</tr>
<tr>
<td>Skeletal muscle</td>
<td>110</td>
<td>$&lt;1$</td>
<td>Pleomorphic sarcoma</td>
<td>15</td>
<td>141</td>
</tr>
<tr>
<td>—</td>
<td>4</td>
<td></td>
<td>Non-Hodgkin’s lymphoma</td>
<td>27</td>
<td>300</td>
</tr>
<tr>
<td>Cultured fibroblasts†</td>
<td>218</td>
<td>2</td>
<td></td>
<td>ENU-treated§</td>
<td>24</td>
</tr>
</tbody>
</table>

*Measured in the RMC assay.
†Normal and neoplastic tissues listed in the same row are paired samples from the same individual.
‡Data for cultured normal dermal fibroblasts are from ref. 9.
§Treated with 1 mg/ml N-ethyl-N-nitrosourea for 1 h.

---

Fig. 3. Tumor mutation spectrum. DNA sequencing of all mutants recovered from tumors showed that C-G to T-A transitions were the most common mutation, and the sequencing permitted distinction between independent random mutational events (gray bars, mutation observed only once) and expansion of mutant clones (white bars, same mutation recovered more than once in the same tumor). Identical mutations observed more than once (expanded mutations) are recorded as one single event; the number of these minority events is indicated by the relatively short length of the white bar extending past the gray bar.
generated by copying the cloned target in reactions containing Taq DNA polymerase, a 5′-biotin-terminated oligonucleotide, and 200 μM dUTP in place of dTTP. The hybridized target is isolated by magnetic separation after complexing with streptavidin coupled to superparamagnetic polymer spheres (Dynabeads; Dynal Biotech, Lake Success, NY). The total number of target molecules in each sample is determined by dilution and PCR amplification. Mutation in the target site TCGA is determined by digesting the hybridized DNA with TaqI, which cleaves the site in the wild-type sequence and fails to cleave if a nucleotide substitution is present at that site. Incubation is carried out with TaqI at 65°C for 1 h, and denaturation is at 95°C for 5 min. The digested product is heat-denatured and rehybridized to the probe. To cleave all wild-type sequences, the restriction digestion protocol is iterated five times. The probe is disabled for further hybridization by digestion with uracil-DNA glycosylase, and the target molecule is diluted and displayed in a 96-well format.

**Mutation Frequency Calculation.** The extent of DNA copy dilution is determined in preliminary experiments so that 1 in 10 wells contains a mutant PCR-amplifiable product as measured with SYBR green by using real-time QPCR. The total number of target molecules in each well is precisely established by using a standard QPCR dilution curve by amplification using control primers that flank the TaqI restriction site (see Fig. 1, row A of the 96-well plate). The mutation frequency is equal to the number of wells that contain a mutant sequence, as determined by using primers that flank the TaqI site (Fig. 1, rows B–H in the 96-well plate), divided by the total number of target base pairs screened. For example, in an experiment where it was determined that 100,000 TaqI sites were seeded in each of the 84 mutant detection wells, we calculate that a total of 33.6 × 10^6 bp were screened, as follows: 84 wells × 100,000 sites per well × 4 bp per TaqI site = 33.6 × 10^6 bp. If 8 mutant TaqI sites were detected by the generation of an ampiclon over the restriction site, the mutant frequency is 2.4 × 10^-7 per bp (8 mutants ÷ 33.6 × 10^6 bp).

We thank A. Blank for editing the manuscript and A. Blank, G. M. Martin, and N. Fausto for insightful comments. This work was funded by Grants CA78885 and CA102029 from the National Cancer Institute (to L.A.L.). A Postdoctoral Fellowship from the Natural Sciences and Engineering Research Council of Canada (NSERC), followed by a Canadian Institutes of Health Research (CIHR) Fellowship provided support for J.H.B. during the completion of these studies.